Methods	O
A	O
randomized	O
,	O
controlled	O
,	O
open	O
-	O
label	O
study	O
of	O
Auxora	O
was	O
conducted	O
in	O
adults	O
with	O
severe	O
or	O
critical	O
COVID	O
-	O
19	O
pneumonia	O
.	O

Patients	O
were	O
randomized	O
2	O
:	O
1	O
to	O
receive	O
three	O
doses	O
of	O
once	O
-	O
daily	O
Auxora	O
versus	O
standard	O
of	O
care	O
(	O
SOC	O
)	O
alone	O
.	O

The	O
primary	O
objective	O
was	O
to	O
assess	O
the	O
safety	B-PrimaryOutcome
and	I-PrimaryOutcome
tolerability	I-PrimaryOutcome
of	I-PrimaryOutcome
Auxora	I-PrimaryOutcome
.	O

Following	O
FDA	O
guidance	O
,	O
study	O
enrollment	O
was	O
halted	O
early	O
to	O
allow	O
for	O
transition	O
to	O
a	O
randomized	O
,	O
blinded	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

